Compounded semaglutide and tirzepatide: what the hype leaves out

What did @haleighweaver5 actually say?

The creator announced that their telehealth company now offers compounded tirzepatide, describing it as "the main ingredient in Mounjaro" and claiming it will "work the exact same" as the brand-name drug. They also cited a starting price of $499, framing compounded tirzepatide as an affordable alternative to Mounjaro, which can run $1,000 or more per month without insurance.

That's the core claim: compounded tirzepatide is functionally identical to Mounjaro and is simply a cheaper version. This is where the video runs into real regulatory and scientific problems, regardless of how appealing the price point sounds to people locked out of brand-name GLP-1 pricing.

Does the science back this up?

Tirzepatide itself is well-studied. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed participants lost up to 20.9% of body weight over 72 weeks, making it one of the most effective weight-loss drugs ever studied. The underlying mechanism, dual GIP and GLP-1 receptor agonism, is genuinely impressive. So the ingredient has solid evidence behind it.

The problem is that compounded versions of tirzepatide have not been tested in the same clinical trials as Mounjaro or Zepbound. Compounding pharmacies are not required to demonstrate bioequivalence, meaning there is no regulatory proof that a compounded formulation delivers the same absorption, purity, or dosing consistency as the FDA-approved product. The FDA has issued multiple warnings about compounded semaglutide and tirzepatide, noting that compounded drugs are not FDA-approved and may carry risks including incorrect dosing and contamination. Claiming these products "work the exact same" is not supported by clinical evidence.

What did they get wrong (or right)?

They got one thing right: tirzepatide is the active ingredient in Mounjaro and Zepbound. That's accurate pharmacology. The price point problem is also real, Mounjaro costs many patients over $1,000 monthly, and access to GLP-1 medications has been a genuine public health issue.

But the claim that compounded tirzepatide will "work the exact same" is misleading, and it's the kind of shortcut that can cause real harm. Compounded drugs are mixed by individual pharmacies and vary in concentration, excipients, and sterility standards. The FDA removed tirzepatide from its drug shortage list in late 2024, which has legal implications for compounders. Pharmacies operating after a shortage designation ends may not be legally authorized to compound tirzepatide at all, depending on their classification. The creator does not address any of this regulatory complexity, which matters a lot when someone is injecting a substance based on a TikTok recommendation.

What should you actually know?

Compounded GLP-1 medications are not FDA-approved, and that is not a technicality. It means no regulator has reviewed the specific formulation being sold for safety, efficacy, or consistency. The American Society of Health-System Pharmacists and the FDA have both flagged risks with compounded GLP-1 products, including reports of dosing errors leading to hospitalizations.

If cost is the barrier, that is a legitimate concern worth solving. Some manufacturers offer patient assistance programs. Telehealth platforms that work with FDA-approved products and licensed prescribers within a real clinical framework can sometimes negotiate better pricing. The answer to a cost problem is not automatically a compounded product with no regulatory oversight. Anyone considering compounded tirzepatide should ask their prescriber specifically which pharmacy is fulfilling the order, whether that pharmacy is 503A or 503B accredited, and whether the pharmacy can provide a certificate of analysis for the batch. Most TikTok ads for these products will not tell you any of that.